Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.
Industry, Sector and Symbol:
- Sector: Industrial Products
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: CDXS
- CUSIP: 19200510
- Previous Close: $4.15
- 50 Day Moving Average: $4.68
- 200 Day Moving Average: $4.54
- 52-Week Range: $2.93 - $5.28
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -18.41
- P/E Growth: -1.49
- Market Cap: $169.00M
- Outstanding Shares: 41,220,000
- Beta: -1
- Net Margins: -10.60%
- Return on Equity: -5.25%
- Return on Assets: -2.69%
Companies Related to Codexis:
- Debt-to-Equity Ratio: 0.04%
- Current Ratio: 2.57%
- Quick Ratio: 2.48%
What is Codexis' stock symbol?
Codexis trades on the NASDAQ under the ticker symbol "CDXS."
Where is Codexis' stock going? Where will Codexis' stock price be in 2017?
3 brokerages have issued 1-year price objectives for Codexis' shares. Their predictions range from $5.50 to $6.25. On average, they expect Codexis' stock price to reach $5.92 in the next twelve months.
When will Codexis announce their earnings?
Codexis is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.
Who owns Codexis stock?
Codexis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (12.85%), FMR LLC (4.99%), Baillie Gifford & Co. (2.88%), Opaleye Management Inc. (2.84%), Renaissance Technologies LLC (2.08%) and William Blair Investment Management LLC (1.71%). Company insiders that own Codexis stock include Bernard J Kelley, Dennis P Wolf, James Lalonde, Patrick Y Yang, Ventures Fund Vii LP Vivo and Vivo Ventures Vii, Llc.
Who sold Codexis stock? Who is selling Codexis stock?
Codexis' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Oxford Asset Management, Renaissance Technologies LLC, William Blair Investment Management LLC and Dimensional Fund Advisors LP. Company insiders that have sold Codexis stock in the last year include Bernard J Kelley, Dennis P Wolf, Ventures Fund Vii LP Vivo and Vivo Ventures Vii, Llc.
Who bought Codexis stock? Who is buying Codexis stock?
Codexis' stock was bought by a variety of institutional investors in the last quarter, including Comprehensive Portfolio Management LLC and State Street Corp.
How do I buy Codexis stock?
Shares of Codexis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Codexis stock cost?
One share of Codexis stock can currently be purchased for approximately $4.05.